Physician profile
Lindsey E Ray
NPI 1861824815
$951.36
in general payments reported to CMS, 2019-2025
15 companies · $55.17 in 2025
The $55.17 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.69 · 2022: $252 · 2023: $518 · 2024: $54.85 · 2025: $55.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $216.86 | 2022-2023 | |
| Novo Nordisk INC | $172.79 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $130.62 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.98 | 2022-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $58.21 | 2022-2023 | Breztri |
| Biohaven Pharmaceutical Holding Company LTD. | $57.60 | 2022 | |
| Xeris Pharmaceuticals, INC. | $48.64 | 2023 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $40.36 | 2022 | |
| Idorsia Pharmaceuticals US INC | $39.37 | 2023 | Quviviq |
| Pfizer INC. | $37.68 | 2023 | |
| Dexcom, INC. | $24.72 | 2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $18.26 | 2023 | Shingrix |
| Lilly USA, LLC | $18.17 | 2023 | Jardiance |
| Medtronic, INC. | $13.77 | 2023 | Closurefast |
| Otsuka America Pharmaceutical, INC. | $13.33 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.